Drugs / BPX-603
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04650451 | Dec 2020 → Dec 2025 | HER2 positive breast carcinoma | Bellicum Pharmaceuticals | Suspended | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BPX-603 | “This is a Phase 1/2, open-label, multicenter, non-randomized study to investigate the safety, tolerability, and clinical activity of HER2-specific dual-switch CAR-T cells,...” NCT04650451 ↗ |
| Modality | Cell therapy | “HER2-specific dual-switch CAR-T cells” NCT04650451 ↗ |